

HPS2-THRIVE Papers' Citations and Credits

1. HPS2-THRIVE Baseline paper

HPS2-THRIVE Collaborative Group, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment, *Eur Heart J* 2013; **34**:1279-1291

Originally published in the European Heart Journal (Oxford University Press).

Original article: <http://eurheartj.oxfordjournals.org/content/34/17/1279>

DOI: 10.1093/eurheartj/eh055

2. HPS2-THRIVE Main Results Paper

From New England Journal of Medicine, The HPS2-THRIVE Collaborative Group, Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients, 2014; **371**:203-212, Copyright ©2014 Massachusetts Medical Society. Reprinted with permission.

Original article: <http://www.nejm.org/doi/full/10.1056/NEJMoa1300955>

DOI: 10.1056/NEJMoa1300955